
FDA Fast-Tracks First Treatment for Alzheimer's Psychosis
A breakthrough therapy for hallucinations and delusions in Alzheimer's patients just earned FDA fast-track status, bringing hope to millions facing a condition with no approved treatments. Results from ongoing trials are expected this fall.














